Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label single-arm, exploratory, two-stage design trial, aiming to
investigate safety and efficacy of AK105 with anlotinib and radiotherapy adjuvant therapy in
MGMT unmethylated newly diagnosed glioblastoma.
Phase:
Phase 2
Details
Lead Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School